Braham Shroot, PhD, has more than 35 years of experience in dermatology drug development.  As Barrier Therapeutics' Chief Scientific Officer, he is responsible for managing all of the company's research and development activities.  Prior to joining Barrier in May 2007, Dr. Shroot served as

Chief Scientific Officer, Vice President of Research and Development for DFB Pharmaceuticals, a specialty pharmaceutical company with branded products that treat skin and soft tissue disorders. During his seven years at DFB, Dr. Shroot oversaw the introduction of several new products in the U.S., in addition to the preparation and submission of U.S. and European regulatory filings for dermatologic and wound care products. Previously, Dr. Shroot spent 13 years in various research and development positions with Galderma S.A., including serving as President, Galderma Research, Inc. in the U.S. and as Vice General Manager of Galderma's R&D organization in France. 

Dr. Shroot began his career in pharmaceuticals at Pfizer, where he was part of the team that developed fluconazole and thioconazole.  Dr. Shroot is an inventor of over 60 patents, has authored several hundred publications, served as editor of several books and is a member of the editorial boards of some prestigious dermatology journals.  He is also a Board member of the Society of Investigative Dermatology, and the Wound Healing Society.  He received his PhD in organic chemistry from Glasgow University, where he also completed his undergraduate studies and earned a Bachelors of Science degree in chemistry.